PL1689378T3 - Nowe zastosowanie związków peptydowych do leczenia ośrodkowego bólu neuropatycznego - Google Patents

Nowe zastosowanie związków peptydowych do leczenia ośrodkowego bólu neuropatycznego

Info

Publication number
PL1689378T3
PL1689378T3 PL04803465T PL04803465T PL1689378T3 PL 1689378 T3 PL1689378 T3 PL 1689378T3 PL 04803465 T PL04803465 T PL 04803465T PL 04803465 T PL04803465 T PL 04803465T PL 1689378 T3 PL1689378 T3 PL 1689378T3
Authority
PL
Poland
Prior art keywords
neuropathic pain
peptide compounds
treating central
novel use
central neuropathic
Prior art date
Application number
PL04803465T
Other languages
English (en)
Inventor
Thomas Stöhr
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03027742A external-priority patent/EP1537862A1/en
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of PL1689378T3 publication Critical patent/PL1689378T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL04803465T 2003-12-02 2004-12-02 Nowe zastosowanie związków peptydowych do leczenia ośrodkowego bólu neuropatycznego PL1689378T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP03027742A EP1537862A1 (en) 2003-12-02 2003-12-02 Novel use of peptide compounds for treating central neuropathic pain
US53089503P 2003-12-22 2003-12-22
EP03029632 2003-12-22
PCT/EP2004/013729 WO2005053667A1 (en) 2003-12-02 2004-12-02 Novel use of peptide compounds for treating central neuropathic pain
EP04803465A EP1689378B1 (en) 2003-12-02 2004-12-02 Novel use of peptide compounds for treating central neuropathic pain

Publications (1)

Publication Number Publication Date
PL1689378T3 true PL1689378T3 (pl) 2009-09-30

Family

ID=34657533

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04803465T PL1689378T3 (pl) 2003-12-02 2004-12-02 Nowe zastosowanie związków peptydowych do leczenia ośrodkowego bólu neuropatycznego

Country Status (16)

Country Link
US (1) US7794987B2 (pl)
EP (1) EP1689378B1 (pl)
JP (1) JP4664924B2 (pl)
KR (1) KR20060111524A (pl)
AT (1) ATE428413T1 (pl)
AU (1) AU2004294714B2 (pl)
BR (1) BRPI0417101A (pl)
CA (1) CA2545543A1 (pl)
DE (1) DE602004020657D1 (pl)
EA (1) EA013590B1 (pl)
ES (1) ES2325995T3 (pl)
IL (1) IL175770A0 (pl)
NO (1) NO20063064L (pl)
NZ (1) NZ546576A (pl)
PL (1) PL1689378T3 (pl)
WO (1) WO2005053667A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da) * 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
JP4664924B2 (ja) 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
AU2005232395B2 (en) * 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
EA014055B1 (ru) * 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US7902401B2 (en) 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
ATE530175T1 (de) * 2006-06-08 2011-11-15 Ucb Pharma Gmbh Therapeutische kombination für schmerzhafte medizinische zustände
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
CN101466390B (zh) 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EA019757B1 (ru) 2006-06-15 2014-06-30 ЮСиБи ФАРМА ГМБХ Фармацевтическая композиция с синергетическим противосудорожным эффектом
CA2672494A1 (en) 2006-12-14 2008-06-19 Nps Pharmaceuticals, Inc. Use of d-serine derivatives for the treatment of anxiety disorders
WO2009053070A1 (en) 2007-10-23 2009-04-30 Schwarz Pharma Ag Compounds for treating demyelination conditions
WO2009121483A1 (en) * 2008-04-02 2009-10-08 Sanofi-Aventis Highly bridged peptides from actinomadura namibiensis
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
BR112013013525A2 (pt) 2010-12-02 2016-10-18 Ucb Pharma Gmbh formulação de liberação controlada sólida de lacosamida para administração oral, composição farmacêutica sólida, e, método para a prevenção, alívio e/ou tratamento de uma doença do sistema nervoso central
KR20210115502A (ko) 2020-03-13 2021-09-27 (주)포에버엔케이 기능성 펩타이드를 함유하는 경피 통증 경감 주사액 조성물
KR102884658B1 (ko) 2021-09-19 2025-11-11 (주)포에버엔케이 기능성 펩타이드를 함유하는 경피 통증 경감 주사액 조성물

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
US5654301A (en) 1985-02-15 1997-08-05 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
ATE166051T1 (de) 1987-08-01 1998-05-15 Takeda Chemical Industries Ltd Zwischenprodukte, ihre herstellung und verwendung zur herstellung alpha-ungesättigter amine
US5962490A (en) 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
YU47834B (sr) 1989-08-10 1996-01-09 Schering Agrochemical Limited Azolni pesticid
TW217417B (pl) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5585358A (en) 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5760038A (en) 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
JP4313435B2 (ja) * 1995-07-24 2009-08-12 トラスティーズ オブ ボストン ユニバーシティー プレグネノロンサルフェート誘導体によるｎｍｄａレセプター活性の抑制
DE19544687A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US6114390A (en) 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
IL126999A (en) 1996-07-24 2002-03-10 Warner Lambert Co Pharmaceutical preparations containing isobutylgaba and its history for use in the treatment of pain
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6048899A (en) 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
AU7937298A (en) 1997-07-08 1999-02-08 Ono Pharmaceutical Co. Ltd. Amino acid derivatives
DK0996435T3 (da) 1997-07-15 2003-01-27 Res Corp Technologies Inc Aminosyrederivater anvendelige til behandling af slagtilfælde
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
WO1999007413A1 (en) 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
GB9816228D0 (en) 1998-07-24 1998-09-23 Pfizer Ltd Isoquinolines
EP1119256B1 (en) 1998-10-09 2003-06-04 Novartis AG Oral combination of lufenuron and nitenpyram against fleas
ATE457169T1 (de) 1998-10-15 2010-02-15 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
DE60037308T2 (de) 1999-09-03 2008-10-30 Actelion Pharmaceuticals Ltd. Bis-sulfonamiden
SE0001373D0 (sv) 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
CA2348847A1 (en) 2000-05-31 2001-11-30 Pfizer Inc. New isoxazole-sulfonamide endothelin antagonists
IL154470A0 (en) 2000-08-17 2003-09-17 Teva Pharma Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
DE60131032T2 (de) 2000-08-25 2008-08-14 Research Corp. Technologies, Inc., Tucson Verwendung von antikonvulsiven Aminosäure zur Behandlung von Migräne
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
AU2002224847A1 (en) 2000-11-21 2002-06-03 U C B, S.A. N-alkylated gaba compounds, processes for their preparation and their use as medicaments
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
CA2434495A1 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
DK1243263T3 (da) * 2001-03-21 2003-03-17 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte
NZ527276A (en) 2001-03-27 2004-11-26 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinoline derivatives as urotensin II receptor antagonists
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
FR2831820B1 (fr) 2001-11-05 2004-08-20 Ethypharm Sa Comprime orodispersible presentant une grande homogeneite et son procede de preparation
WO2003099338A2 (en) 2002-05-17 2003-12-04 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
CA2505361A1 (en) 2002-11-11 2004-05-27 Bayer Healthcare Ag Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US20040213842A1 (en) 2003-01-30 2004-10-28 Dynogen Pharmaceuticals, Inc. Methods of treating gastrointestinal tract disorders using sodium channel modulators
EP1589959A2 (en) 2003-01-30 2005-11-02 Dynogen Pharmaceuticals Inc. Methods of treating lower urinary tract disorders using sodium channel modulators
US20040266743A1 (en) 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
EP1678121A4 (en) 2003-10-24 2007-07-25 Exelixis Inc MODULATORS OF TAO KINASES AND METHODS OF USE
JP4664924B2 (ja) 2003-12-02 2011-04-06 ウーツェーベー ファルマ ゲーエムベーハー 中枢神経因性疼痛の治療のためのペプチド化合物の新規使用
EP1537862A1 (en) 2003-12-02 2005-06-08 Schwarz Pharma Ag Novel use of peptide compounds for treating central neuropathic pain
EP1541138A1 (en) 2003-12-05 2005-06-15 Schwarz Pharma Ag Novel use of peptide compounds for treating status epilepticus or related conditions
US20060009384A1 (en) 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (en) 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
AU2005232395B2 (en) 2004-04-16 2010-09-09 Schwarz Pharma Ag Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
EA014055B1 (ru) 2004-08-27 2010-08-30 Шварц Фарма Аг Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами
EP1642889A1 (en) 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
EP1688137A1 (en) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 for add-on therapy of schizophrenia
US20060252749A1 (en) 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070043120A1 (en) 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US20070048372A1 (en) 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia

Also Published As

Publication number Publication date
ES2325995T3 (es) 2009-09-28
US20050209163A1 (en) 2005-09-22
AU2004294714A1 (en) 2005-06-16
AU2004294714B2 (en) 2009-12-10
BRPI0417101A (pt) 2007-02-06
EP1689378B1 (en) 2009-04-15
JP4664924B2 (ja) 2011-04-06
JP2007513119A (ja) 2007-05-24
KR20060111524A (ko) 2006-10-27
EP1689378A1 (en) 2006-08-16
NO20063064L (no) 2006-09-01
DE602004020657D1 (de) 2009-05-28
NZ546576A (en) 2009-05-31
EA013590B1 (ru) 2010-06-30
US7794987B2 (en) 2010-09-14
HK1095749A1 (zh) 2007-05-18
CA2545543A1 (en) 2005-06-16
EA200601074A1 (ru) 2006-10-27
ATE428413T1 (de) 2009-05-15
WO2005053667A1 (en) 2005-06-16
IL175770A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
IL175770A0 (en) Novel use of peptide compounds for treating central neuropathic pain
PL369530A1 (pl) Związki chemiczne
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
EP1432714A4 (en) CHEMICAL COMPOUNDS
TW200626068A (en) Active compounds for seed treatment
SG145694A1 (en) Novel compounds
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
MY135477A (en) 2-(2,6-dichlorophenyl)-diarylimidazoles
DE602004021472D1 (en) Pyrimiidinverbindungen
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
AU3831301A (en) Method for treating ocular pain
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
MXPA05011233A (es) Vectores peptidicos.
WO2004087073A3 (en) Treatment of demyelinating conditions
TW200510398A (en) Novel compounds
MXPA04003755A (es) Endoprotesis vasculares.
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
TW200604149A (en) Norbornane based cycloaliphatic compounds containing nitrile groups
IL189286A0 (en) Novel cysteine protease inhibitors and their therapeutic applications
DE602004012146D1 (en) Pyrazolopyrimidine
GB0207653D0 (en) Methods of using lamellar bodies for therapeutic purposes
UA87117C2 (ru) Применение пептидных соединений для лечения центральной невропатической боли
MXPA03008946A (es) Metodos para sintetizar compuestos que contienen fenol.
TW200512009A (en) Hair treatment compositions
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions